Last reviewed · How we verify
Combination of trabectedin with durvalumab
At a glance
| Generic name | Combination of trabectedin with durvalumab |
|---|---|
| Sponsor | Institut Bergonié |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Constipation
- Fatigue
- Nausea
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- CPK increased
- Fever
- GGT increased
- Lymphocyte count decreased
- Neutrophil count decreased
- Acute kidney injury
- Anemia
Key clinical trials
- Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. (PHASE1)
- Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: